A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Exclusion Criteria

• •Previous treatment with cytotoxic drugs within 4 weeks before enrollment
• •Previous treatment with endocrine or small molecule drug tyrosine kinase inhibitor TKI within 2 weeks before enrollment
• •Patients who received prior treatment with any CDK4/6 inhibitor, everolimus or fulvestant
• •HER2 positive
• •Patients with major surgery within 4 weeks, severe or unstable systemic disease, unstable/symptomatic CNS metastasis, other malignant tumors, ILD, clinical significant cardiac disease, bleeding or embolic disease, active infectious disease, conditions affecting drug swallow and absorption, etc
• •Pregnancy or lactation
• •Other conditions considered not appropriate to participate in this trial by the investigators